| INTRODUC TI ON
Peptide vaccination immunotherapy using human leukocyte antigen (HLA) class I-binding short peptides has been used to induce tumor-specific cytotoxic T lymphocytes (CTL) in patients with various cancers, because various tumor-associated antigens (TAA) have been identified. 1, 2 Generally, TAA-derived peptide vaccination induces antigen-specific CTL in cancer patients. We have also observed antigen-specific CTL responses in patients with various carcinomas and sarcomas. 3, 4 For the efficacy of peptide vaccination immunotherapy, endogenous expression of the target peptide/HLA on cancer cells is required. However, it is difficult to evaluate the expression status of a peptide/HLA complex because of the lack of a soluble T-cell receptor (TCR) reacting with TAA with high avidity.
For efficacy of peptide vaccination immunotherapy for patients with cancer, endogenous expression of the target peptide/human leukocyte antigen (HLA) on cancer cells is required. However, it is difficult to evaluate the expression status of a peptide/HLA complex because of the lack of a soluble T-cell receptor (TCR) that reacts with tumor-associated antigen (TAA) with high avidity. In the present study, we developed two soluble TCR-multimers that were each directed to TAA, survivin-2B
(SVN-2B) and PBF in the context of HLA-A24 (SVN-2B TCR-multimer and PBF TCRmultimer, respectively), from CTL clones that were established from peptidevaccinated patients. Both TCR multimers could recognize cognate peptide-pulsed antigen-presenting cells, C1R-A24 cells, in a CD8-independent method. Moreover, the PBF TCR-multimer successfully recognized a PBF peptide naturally presented on HLA-A24 + PBF + osteosarcoma cells. Taken together, the results indicated that a TCRmultimer might be useful for detection of a TAA-derived peptide presented by HLA in patients receiving immunotherapy.
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We previously reported an artificial monoclonal antibody (mAb), D12, directed to osteosarcoma antigen PBF-derived peptide/HLA-A2 complex on osteosarcoma cells. 5 mAb D12 showed high affinity and characteristics of TCR-like specificity, but some cross-reactivity to other antigens was observed when using a mAb D12 multimer.
Generally, the advantage of TCR-like mAbs is their high affinity.
However, regarding the mAb D12, the specificity of TCR might be superior to that of TCR-like mAb.
In the present study, we successfully developed two soluble TCR-multimers that were each directed to TAA, survivin-2B and PBF in the context of HLA-A24 (SVN-2B TCR-multimer and PBF TCRmultimer, respectively) from CTL clones that were established form peptide-vaccinated patients. Both TCR multimers could recognize cognate peptide-pulsed antigen-presenting cells, C1R-A24 cells.
Although SVN-2B TCR-multimer failed to recognize an endogenous peptide/HLA complex, PBF TCR-multimer successfully recognized the PBF peptide naturally presented on HLA-A24 + PBF + osteosarcoma cells.
| MATERIAL S AND ME THODS
The present study was carried out in accordance with the guidelines The patients, their families, and healthy donors provided informed consent for the use of blood samples in our research.
| Peptides
Survivin-2B (SVN-2B) peptide (AYACNTSTL), 6 PBF peptide (AYRPV SRNI) 7 and HIV peptide (RYLRDQQLL) were synthesized (>95% purity) by Sigma-Aldrich Japan (Ishikari, Japan).
| Cells, antibodies, tetramers and flow cytometry analysis
The following cells, antibodies, and tetramers were used for staining and cell sorting. C1R-A24 cells, lymphoblastoid C1R cells transfected with HLA-A*24:02 cDNA, were a kind gift from Dr M.
Takiguchi (Kumamoto University School of Medicine, Japan). Sup-T1 cell lines were purchased from the Riken Cell Bank (Tsukuba, Japan). 
| CTL clones
Survivin-2B or PBF-specific CTL lines were established in our laboratory using PBMC from SVN-2B or PBF peptide-vaccinated HLA-A24 + donors, respectively, by a mixed lymphocyte peptide culture (MLPC) according to the method described by Karanikas et al. 9 Briefly, antigenic peptides were directly added to PBMC at 10 μg/ mL suspended in a 2-mL medium in a 24-well plate (BD Biosciences), and cultures were maintained at 37°C in 5% CO 2 . On day 2, recom- 
| Cytotoxicity assay
Antigen-specific lytic activity of CTL clone ITG-MT3 was evaluated by using a 
| Transfection of TCR genes in lymphoma cells
T-cell receptor α chain/pCDNA3.1 and TCR β chain/pEF6/Myc-His plasmids (10 μg each) were transduced into lymphoma cells by electroporation using the Neon Transfection system (Thermo Fisher Scientific), and selection was done in a medium containing 0.5 mg/ mL G418 (Roche Diagnostics, Basel, Switzerland) and 5 μg/mL blasticidin (Thermo Fisher Scientific). Expression levels of the transduced genes were assessed by flow cytometry with tetramer staining.
| Analysis of cytokine production and reporter gene assay
An IFN-γ ELISPOT assay was carried out as described previously using a human IFN-γ ELISPOT set (BD Biosciences). 12 Briefly, nitrocellulosebottomed 96-well plates were coated with an anti-IFN-γ antibody.
Wells were washed with PBS and blocked for 2 hours by 10% FBS/ RPMI1640 medium. After washing with PBS, TCR-transfected cells were added. Peptide-pulsed C1R-A24 cells were then added to each well, and the plates were incubated overnight. The following day, media were discarded, and the wells were washed prior to addition of a biotinylated secondary antibody. The plates were incubated for 2 hours and washed, and avidin-enzyme conjugate was added to each well. The plates were incubated at room temperature for 1 hour, and a 3-amino-9-ethylcarbazole (AEC) substrate (BD Biosciences) was added to each well and incubated at room temperature for approximately 15 minutes. The reaction was terminated by washing with water, and detectable spots were counted. The NFAT reporter gene BirA-site and multimerized with PE-leveled streptavidin.
| Human leukocyte antigen-A24 blocking assay
Cells were first treated with mouse IgG1 isotype control or anti-HLA-A24 mAb clone C7709A2.6 (kindly provided by Dr P. G. Coulie, Ludwig Institute for Cancer Research, Brussels Branch). After incubation at 4°C for 30 minutes, cells were washed once and stained with TCR-multimers at 4°C for 1 hour. After TCR-multimer staining, cells
were washed once and analyzed by flow cytometry using FACSCalibur.
CellQuest software and FlowJo software were used for data analysis.
| Surface plasmon resonance analysis
Surface plasmon resonance analysis was carried out using a ProteOn XPR36 (Bio-Rad Laboratories, Hercules, CA, USA) according to the protocol described by Nahshol et al. 13 Briefly, 1 μg/mL of a bioti- 
| T-cell receptor-multimer staining and immunofluorescence microscopy
Cells were first stained with TCR-multimers at 4°C for 1 hour. The cells were fixed with 4% paraformaldehyde and stained with DAPI.
Immunofluorescence microscopy was carried out using BZ-9000 (Keyence Corporation, Osaka, Japan) and AxioObserver.Z1 (Carl Zeiss, Oberkochen, Germany).
| Statistical analysis
Results are given as means and standard deviations. Statistical comparisons were made using two-tailed Student's t tests; P-values of .05 were considered significant.
| RE SULTS

| Induction of antigen-specific CTL clones with high avidity
We first attempted to establish SVN-2B-or PBF-specific CTL as the source of TCR genes. CTL were induced using PBMC from A24 Figure 1B) . Moreover, FKS-D11P cells showed strong and specific cytotoxicity against C1R-A24 cells that were pulsed with A24-PBF peptides at a lower effector : target (E:T) ratio ( Figure 1B ).
These results indicated that FKS-D11P TCR could recognize these A24/epitope peptide complexes with higher avidity than that of ITG-MT3 TCR. 
| Clonotyping of TCR
| T-cell receptor-transduced T-cell lymphoma cell lines specifically recognized antigenic peptidepresented C1R-A24 cells
To evaluate TCR reactivity to SVN-2B or PBF tetramers, we tran- 
| CD8 dependency of HLA-TCR interaction
CD8 molecule binds to the nonpolymorphic aspect of the HLA class I molecule and sometimes augments TCR-HLA interaction. 14 To investigate CD8 dependency of TCR-HLA interaction, ITG-MT3 TCR and FKS-D11P TCR genes were transfected to J.RT3-T3.5 cells, CD8 and TCR β chain-deficient mutant Jurkat cells. 15 As a result, both transduced TCR could react with specific tetramers, but the CD8-dependent WT1 TCR 11 could not react with the WT1 tetramer ( Figure 4A ). These results suggested that both ITG-MT3 and FKS-D11P TCR could react with the peptide/HLA complex in a CD8-independent way.
In addition, two anti-CD8 clones were used to assess the inhibitory effects of tetramer staining. Clone RFT-8 has an HLA-CD8
interaction-inhibition effect and clone T8 did not have any HLA-CD8 interaction-inhibition effect. As shown in Figure 4B , reactivities with specific tetramers of both ITG-MT3 TCR and FKS-D11P TCR were not influenced by the anti-CD8 mAb clone RFT-8. In contrast, CD8-dependent WT1 TCR decreased reactivity with the WT1 tetramer by clone RFT-8. The other anti-CD8 mAbs showed compatible reactivities ( Figure S3 and Table S1 ). These results strongly suggested that both ITG-MT3 TCR and FKS-D11P TCR could react with HLA in a CD8-independent way.
| Generation of a recombinant TCR-multimer
To detect specific HLA/peptide complexes without viable cells, we tried to produce a TCR-multimer using the extracellular domain of recombinant TCR α/β proteins. The construct of TCR-monomers is shown in Figure 5A . Recombinant proteins of TCR α/β chains were dimerized with the fos-jun leucine zipper, followed by BirA site biotinylation (TCRmonomer). A TCR-monomer was multimerized with streptavidin-PE by biotin-avidin reaction (TCR-multimer). TCR-multimers of ITG-MT3 and FKS-D11P were designated as SVN-2B TCR-multimer and PBF TCRmultimer, respectively. SVN-2B and PBF TCR-multimers could detect more than 1 μg/mL of several specific peptide-pulsed C1R-A24 cells by FACS ( Figure 5B,C) . Reactivities of TCR-multimers also depended on their concentrations ( Figure S4 ) and on the concentrations of the pulsed peptides ( Figures S5 and S6 ). In addition, these reactivities of TCR-multimers were blocked by anti-HLA-A24 mAb C7709A2.6
( Figure 5D ,E). These results indicated the both TCR-multimers could react with each specific peptide in an HLA-A24 restriction method similar to TCR expressed on CTL clones and T-cell lymphoma cell lines.
The reactions of TCR-multimers against specific peptides could also be detected by immunofluorescence microscopy ( Figure 5F ,G). Positive staining was observed in the cytoplasmic membrane as a diffuse circulation pattern. These results also suggested that numerous peptides were presented by HLA-A24 molecules on such target cells pulsed with peptides at high concentrations.
To determine the molecular affinity between the TCR and HLA/ peptide complex, we carried out surface plasmon resonance analysis 
| D ISCUSS I ON
In the present study, we established CTL clones with high avidity For constructing a probe with TCR-like specificities, single-chain variable fragment (scFv) phage display library technology is very useful. 16 We previously established a scFv clone reacting with a PBF peptide naturally presented by HLA-A2 + osteosarcoma cells using phage display scFv libraries. TCR were also higher than the general affinity of TCR. In addition, both ITG-MT3 TCR and FKS-D11P TCR showed CD8-independent interactions between the TCR and HLA/peptide complex. This might be because peptide vaccination had successfully elicited high-affinity TCR with CD8-independency in vivo. Our observations suggested that CD8-independency of TCR is also important for construction of a TCR-multimer with the same high affinity as that of TCR.
In the present study, we used only established CTL clones recognizing vaccinated epitopes as the source of TCR to construct a TCR multimer. By using this strategy, immunodominant TCR directed to unknown antigens including neoantigens among TIL (Tumor-infiltrating lymphocyte) in primary cancer tissues could not be obtained. Deep sequencing of TRAV and TRBV combined with 5′RACE of dominant repertoires might be useful to construct immunodominant TCR multimers reacting with unknown antigens.
In a clinical setting, primary biopsy specimens might be used to evaluate the HLA/peptide complex on osteosarcoma cells. However, the expression status of target antigens in metastatic or recurrent lesions might be different from that in the primary lesion. Difficulty in assessing lesions of solid cancer including osteosarcoma is an important problem. In the future, if circulating osteosarcoma cells can be isolated as a liquid biopsy, adequate evaluation of the HLA/peptide complex on osteosarcoma cells might be easier.
In conclusion, we successfully generated TCR-multimers reacting with HLA/TAA-derived peptides, HLA-A24/SVN-2B peptide and HLA-A24/PBF peptide complexes. Moreover, the PBF TCR-multimer with high avidity could react with a naturally presented PBF peptide on osteosarcoma cell lines. Taken together, the results indicated that a TCR-multimer might be useful for the detection of target antigens in immunotherapy.
